Cinclus’ acid inhibition

How the AZ veterans behind newco Cinclus aim to treat severe GERD

Cinclus Pharma AG is developing a fast-acting potassium-competitive acid blocker designed to last longer than proton pump inhibitors and marketed P-CABs to treat severe erosive gastrointestinal reflux disease.

PPIs such as Nexium esomeprazole and Prilosec omeprazole from AstraZeneca plc are standard of care for gastrointestinal reflux disease (GERD) and other acid related diseases.

However, according to CEO Kjell Andersson, “due to the chemical nature of PPIs as well as their mechanism of action, it

Read the full 747 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers